PL3139925T3 - Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu - Google Patents

Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu

Info

Publication number
PL3139925T3
PL3139925T3 PL15724438T PL15724438T PL3139925T3 PL 3139925 T3 PL3139925 T3 PL 3139925T3 PL 15724438 T PL15724438 T PL 15724438T PL 15724438 T PL15724438 T PL 15724438T PL 3139925 T3 PL3139925 T3 PL 3139925T3
Authority
PL
Poland
Prior art keywords
valbenazine
hyperkinetic
treatment
motion disorders
dosage scheme
Prior art date
Application number
PL15724438T
Other languages
English (en)
Inventor
Christopher F. O'Brien
Original Assignee
Neurocrine Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences, Inc. filed Critical Neurocrine Biosciences, Inc.
Publication of PL3139925T3 publication Critical patent/PL3139925T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL15724438T 2014-05-06 2015-05-06 Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu PL3139925T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06
PCT/US2015/029519 WO2015171802A1 (en) 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
EP15724438.5A EP3139925B1 (en) 2014-05-06 2015-05-06 Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders

Publications (1)

Publication Number Publication Date
PL3139925T3 true PL3139925T3 (pl) 2022-03-21

Family

ID=53264772

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15724438T PL3139925T3 (pl) 2014-05-06 2015-05-06 Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu
PL21178882.3T PL3936130T3 (pl) 2014-05-06 2015-05-06 Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL21178882.3T PL3936130T3 (pl) 2014-05-06 2015-05-06 Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu

Country Status (24)

Country Link
US (3) US20170071932A1 (pl)
EP (3) EP3936130B1 (pl)
JP (4) JP6635945B2 (pl)
KR (5) KR20240011255A (pl)
CN (3) CN112741836A (pl)
AU (1) AU2015256012B2 (pl)
CA (1) CA2947736C (pl)
CY (1) CY1125058T1 (pl)
DK (2) DK3139925T3 (pl)
ES (2) ES2976207T3 (pl)
FI (1) FI3936130T3 (pl)
HR (2) HRP20240459T1 (pl)
HU (2) HUE057839T2 (pl)
IL (1) IL248745B (pl)
LT (2) LT3936130T (pl)
MX (1) MX387625B (pl)
NZ (1) NZ725826A (pl)
PL (2) PL3139925T3 (pl)
PT (2) PT3139925T (pl)
RS (2) RS65359B1 (pl)
RU (1) RU2753740C2 (pl)
SI (2) SI3936130T1 (pl)
SM (2) SMT202400199T1 (pl)
WO (1) WO2015171802A1 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL284874B2 (en) * 2015-10-30 2023-10-01 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
LT3394057T (lt) 2015-12-23 2022-06-27 Neurocrine Biosciences, Inc. Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
EP3473623B1 (en) * 2016-06-29 2020-07-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of nbi-98854, preparation method therefor and use thereof
TW202345829A (zh) * 2016-12-02 2023-12-01 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
WO2018130345A1 (en) 2017-01-10 2018-07-19 Sandoz Ag Crystalline valbenazine free base
KR20230169457A (ko) 2017-01-27 2023-12-15 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CA3054238A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
CA3057543A1 (en) * 2017-04-01 2018-10-04 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
RU2768738C2 (ru) * 2017-04-01 2022-03-24 Адептио Фармасьютикалз Лимитед ПРИМЕНЕНИЕ (-)-α-ДИГИДРОТЕТРАБЕНАЗИНА ИЛИ ЕГО КОМБИНАЦИИ С (+)-α-ДИГИДРОТЕТРАБЕНАЗИНОМ В ЛЕЧЕНИИ ГИПЕРКИНЕТИЧЕСКОГО ДВИГАТЕЛЬНОГО РАССТРОЙСТВА, А ТАКЖЕ СООТВЕТСТВУЮЩИЕ СПОСОБЫ
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
US20200179352A1 (en) * 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
RS66714B1 (sr) 2017-09-21 2025-05-30 Neurocrine Biosciences Inc Formulacija visoke doze valbenazina i sastavi, postupci i kompleti povezani sa njim
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
MX2020003421A (es) * 2017-10-10 2020-07-20 Neurocrine Biosciences Inc Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
CA3081709A1 (en) * 2017-11-08 2019-05-16 Yuhua Li Esters of dihydrotetrabenazine
EP3733666B1 (en) 2017-12-26 2022-09-21 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of valbenazine di-p-toluenesulfonate, preparation method thereof and use thereof
DK3784237T3 (da) * 2018-04-25 2024-01-08 Shinkei Therapeutics Inc Indretning til transdermal levering af tetrabenazin
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
EP3806856A1 (en) 2018-06-14 2021-04-21 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
MA53239A (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
MX2021013132A (es) * 2019-05-09 2021-11-25 Neurocrine Biosciences Inc Metodos para la administracion de ciertos inhibidores del transportador 2 vesicular de monoaminas (vmat2).
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2081929T3 (da) * 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
EP2083744A4 (en) * 2006-11-09 2013-08-28 Univ New York DEGRADED GLASS / ZIRCONIUM / GLASS STRUCTURES FOR DAMAGE-RESISTANT DENTAL AND ORTHOPEDIC CERAMIC PROSTHESES
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
CA2736409C (en) 2008-09-18 2017-07-11 Auspex Pharmaceutical, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
JP2013501810A (ja) * 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
CA2801061A1 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
CA2883641C (en) * 2012-09-18 2021-09-14 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2938581C (en) * 2014-02-07 2023-02-28 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof

Also Published As

Publication number Publication date
HRP20240459T1 (hr) 2024-06-21
FI3936130T3 (fi) 2024-04-23
KR20200133003A (ko) 2020-11-25
KR20220140647A (ko) 2022-10-18
EP3936130B1 (en) 2024-02-14
US20170071932A1 (en) 2017-03-16
WO2015171802A1 (en) 2015-11-12
JP2019218407A (ja) 2019-12-26
JP2021191799A (ja) 2021-12-16
JP2024153782A (ja) 2024-10-29
CN112741836A (zh) 2021-05-04
KR20160147044A (ko) 2016-12-21
ES2976207T3 (es) 2024-07-26
RS62782B1 (sr) 2022-01-31
SI3139925T1 (sl) 2022-04-29
LT3936130T (lt) 2024-04-25
HUE066361T2 (hu) 2024-07-28
EP4389227A3 (en) 2024-09-04
HRP20220025T1 (hr) 2022-04-01
PL3936130T3 (pl) 2024-06-10
CN106456629A (zh) 2017-02-22
AU2015256012A1 (en) 2016-11-24
PT3139925T (pt) 2022-01-26
US20200101063A1 (en) 2020-04-02
CN112741835A (zh) 2021-05-04
PT3936130T (pt) 2024-04-17
AU2015256012B2 (en) 2020-07-23
SMT202400199T1 (it) 2024-07-09
DK3139925T3 (da) 2021-12-20
EP3936130A1 (en) 2022-01-12
DK3936130T3 (da) 2024-03-25
MX387625B (es) 2025-03-18
RS65359B1 (sr) 2024-04-30
EP3139925A1 (en) 2017-03-15
IL248745A0 (en) 2017-01-31
CY1125058T1 (el) 2023-06-09
LT3139925T (lt) 2022-01-25
JP6635945B2 (ja) 2020-01-29
US20210196702A1 (en) 2021-07-01
KR20250029267A (ko) 2025-03-04
ES2904526T3 (es) 2022-04-05
HUE057839T2 (hu) 2022-06-28
SMT202200193T1 (it) 2022-07-21
IL248745B (en) 2022-07-01
CA2947736A1 (en) 2015-11-12
RU2016147523A3 (pl) 2018-12-28
JP2017514850A (ja) 2017-06-08
EP3139925B1 (en) 2021-12-01
MX2016014429A (es) 2017-04-06
NZ725826A (en) 2023-05-26
CA2947736C (en) 2023-04-18
EP4389227A2 (en) 2024-06-26
SI3936130T1 (sl) 2024-05-31
KR20240011255A (ko) 2024-01-25
RU2016147523A (ru) 2018-06-08
RU2753740C2 (ru) 2021-08-23

Similar Documents

Publication Publication Date Title
HUS2100037I1 (hu) Vegyületek gerinc eredetû izomsorvadás kezelésére
PL3936130T3 (pl) Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu
IL247452A0 (en) Compounds for treatment of complement mediated disorders
IL256166B (en) Compounds for use in treating neuromuscular disorders
IL253945A0 (en) kdm1a inhibitors to treat the disease
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
HUE059303T2 (hu) Acetilkolin-észteráz-gátlók bõrbetegségek kezelésére
IL249502A0 (en) Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases
HUE037179T2 (hu) Gyógyászati kompozíciók izom-rendellenességek kezelésére
SG11201608729RA (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
HUE053443T2 (hu) Heteroaril vegyületek szembetegségek kezelésére
IL280227A (en) Arimoclomol for treating glucocerebrosidase associated disorders
GB201408387D0 (en) Treatment of respiratory disorders
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose
HUE070257T2 (hu) Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére
IL259381B (en) Mirabegron for the treatment of retinal diseases
GB201410407D0 (en) Treatment of chagas disease
MD3364975T2 (ro) Combinație de trazodonă și gabapentină pentru tratamentul durerii
PL3164110T3 (pl) Kompozycje farmaceutyczne do leczenia łuszczycy
HUE052088T2 (hu) Neridronsav vagy sójának alkalmazása osteoarthrosis kezelésére
HUE049392T2 (hu) Paroxizmális súlyos fájdalom kezelése
ES1113580Y (es) Dispositivo dental para el tratamiento de la onicofagia
GB201621398D0 (en) Treatment of emt-associated disease
GB201504413D0 (en) Treatment of disease
GB201602784D0 (en) New treatment of CFTR-related disorders